The aim of the present study was to investigate the role of the cyclic phosphodiesterase type 4 (PDE4) in human lung and to determine the effects of NCS 613, a new PDE4 inhibitor, on lung inflammation and bronchial hyperresponsiveness.
We studied the activity of a novel PDE4 inhibitor, CHF6001, both <i>in vitro</i> in human cells and <i>in vivo</i>, using bioluminescence imaging (BLI) in mice lung inflammation.